Finnish is available via eTranslation, the European Commission's machine translation service.
Translate to Finnish | Important information about machine translation
The Committee for Medicinal Products for Human Use (CHMP) assesses PRIME eligibility requests and adopts recommendations on whether medicines are eligible for the scheme.
EMA publishes the recommendations monthly on this page and in the CHMP Highlights and notifies applicants by letter.
The recommendations include positive and negative outcomes, with limited information on the product type, intended indication, level of supporting data and type of applicant (such as SMEs, academia or other organisations).
For medicines granted PRIME support, CHMP publishes the name of the active substance / international non-proprietary name (INN). This information is not published for negative outcomes.
EMA also updates a list of medicines currently in the PRIME scheme on a monthly basis. EMA removes medicines from the list when:
For more information on the PRIME scheme, see:
The charts show cumulative figures for PRIME eligibility requests up to the latest CHMP meeting.
Use the chart menu to view the data as a table or download the data in Excel and other available formats.
Chart term explanation:
Out of scope - out of scope applications are not included in the breakdown by type of applicants or therapeutic areas.
An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.
The tracking of updates begins in September 2026.
6 October 2026